DEF: BD Unveils 'Excellence Unleashed' Strategy, Reports Record FY25

Becton, Dickinson and Company announces its new 'Excellence Unleashed' growth strategy, following record fiscal year 2025 revenues of $21.8 billion and a strategic portfolio simplification.

Summary

• The company is culminating its BD2025 strategy and launching a new vision called 'Excellence Unleashed' to drive future growth.
• An agreement has been announced to combine the Biosciences and Diagnostic Solutions business with Waters Corp. via a tax-efficient Reverse Morris Trust (RMT) transaction, positioning BD as a dedicated medical technology company.
• The Waters RMT transaction is expected to generate approximately $4 billion in cash proceeds, with at least half committed to share repurchases and the balance for debt repayment.
• Fiscal year 2025 saw record total revenues of $21.8 billion, GAAP EPS of $5.82, and record adjusted diluted EPS of $14.40.
• Net cash from continuing operations for FY25 was approximately $3.4 billion.
• The company achieved its most prolific period of organic growth in its 128-year history over the past five years.
• BD Excellence, the company's lean operating system, has driven significant improvements, including a 50% reduction in manufacturing non-conformances and over 8% year-over-year productivity gains, leading to the lowest CapEx-to-revenue ratio in over a decade.
• Over 25 new products were launched across high-growth end-markets in FY25.
• Shareholders will vote on the election of thirteen director nominees, ratification of Ernst & Young LLP as the independent auditor, an advisory vote on named executive officer compensation, and an amendment to the 2004 Employee and Director Equity-Based Compensation Plan to increase authorized shares by 3,935,000.
• The company returned $2.2 billion to shareholders in fiscal year 2025 through share repurchases and dividends, marking its 54th consecutive year of dividend increases.

Sentiment

Score: 8

Explanation: The filing presents a very positive outlook with strong financial performance, strategic transformation, and robust governance, despite minor challenges like tariffs and a shareholder proposal issue. The strategic moves and financial results indicate strong management and future potential.

Positives

• Achieved record fiscal year 2025 revenue of $21.8 billion.
• Reported record adjusted diluted EPS of $14.40 for fiscal year 2025.
• Experienced the most prolific period of organic growth in its 128-year history over the past five years.
• Became a leader among its peer group in gross and operating margin expansion.
• The strategic combination of Biosciences and Diagnostic Solutions with Waters Corp. is expected to unlock significant value for shareholders and simplify the portfolio.
• Committed to allocating at least half of the expected $4 billion cash proceeds from the Waters RMT transaction for share repurchases.
• BD Excellence initiatives resulted in a 50% reduction in manufacturing non-conformances and over 8% year-over-year productivity improvement.
• Achieved the lowest CapEx-to-revenue ratio in over a decade.
• Returned $2.2 billion to shareholders in fiscal year 2025 through share repurchases and dividends.
• Extended its long-standing recognition as a member of the S&P 500 Dividend Aristocrats Index with its 54th consecutive year of dividend increases.
• Launched over 25 new products across high-growth end-markets, including the AI-enabled BD Incada platform and next-generation BD Pyxis Pro Medication Dispensing platform.
• Maintains robust corporate governance practices, including annual election of directors, majority voting, a strong lead director structure, and proxy access.
• A pay equity assessment in 2025 showed that, on average, both women and men are paid within an expected range after controlling for legitimate differentiating factors.

Negatives

• The calculated financial performance factor for the Performance Incentive Plan (PIP) was 77% of target, which was then adjusted to 85% due to the impact of unanticipated tariffs and underperformance in certain business units.
• GAAP EPS of $5.82 is significantly lower than the Adjusted Diluted EPS of $14.40, indicating substantial non-GAAP adjustments.
• A shareholder proposal was excluded from the proxy statement due to a procedural defect, specifically the failure to meet ownership thresholds.

Risks

• Cybersecurity and data privacy risks are overseen by the Audit Committee and managed by the Chief Information Security Officer (CISO) and Vice President, Research and Development, Product Security (VP of Product Security).
• Product quality and patient safety risks are overseen by the Quality and Regulatory Committee (QRC) and managed through the Inspire Quality program.
• Risks associated with compensation programs are reviewed by management and overseen by the Compensation Committee to avoid excessive risk-taking.
• The company's financial performance is subject to the impact of foreign currency exchange rates, which are adjusted for in performance metrics like the PIP.
• Unanticipated tariffs imposed by the U.S. government and reciprocal tariffs by trading partners have negatively impacted financial results and required adjustments to compensation metrics.
• Potential conflicts of interest exist with director-affiliated organizations, such as the anticipated investment in TEAMFund, LP II, established by director Timothy Ring.
• Legal matters, including product liability and an SEC investigation related to BD Alaris infusion pumps, have resulted in charges and estimated liabilities.
• Regulatory compliance risks are managed through processes and procedures overseen by the QRC, particularly concerning new regulations like the European Union Medical Device Regulation.

Future Outlook

The company is launching its 'Excellence Unleashed' growth strategy, aiming to accelerate growth and deliver an exceptional customer experience through world-class commercial capabilities and a culture of relentless execution. It plans to capitalize on its unique position to create breakthrough innovations in high-growth markets, leveraging AI, robotics, and new material science, and will significantly increase investment in its innovation pipeline. The company expects to deliver exceptional quality, reliable supply, and consistent cash flow growth, with operational excellence serving as a foundation for reinvestment. Following the Waters RMT transaction, the company is committed to allocating at least half of the expected $4 billion cash proceeds to share repurchases and the balance to debt repayment, while continuing progress towards a ~2.5x net leverage target. An investment in TEAMFund, LP II is anticipated to close in fiscal year 2026.

Management Comments

• "This year marks the culmination of our BD2025 strategy and the beginning of a bold new vision to Unleash Excellence across BDs business." Tom Polen, Chairman, CEO and President
• "We aim to deliver world-class commercial execution, a high-impact innovation pipeline and unmatched quality and supply reliability — all in the service of a new chapter of growth." Tom Polen
• "Over the past five years, BD has achieved the most prolific period of organic growth in our 128-year history, built and scaled multiple unique high-growth platforms and developed a strong innovation pipeline in attractive end markets." Tom Polen
• "During this period, we became a leader among our peer group in gross and operating margin expansion — driven by the creation and scale of BD Excellence, our lean operating system." Tom Polen
• "This strategic move simplifies our portfolio and unlocks value for our shareholders through ownership in the new life sciences company." Tom Polen (referring to the Waters RMT transaction)
• "The transaction also enhances our capital allocation framework, with a commitment to allocating at least half of the expected $4 billion cash proceeds for share repurchases with the balance for debt repayment following the closing." Tom Polen
• "Our strategy is to achieve excellence everywhere." Tom Polen
• "We are already making progress, including introducing a new vertical business unit operating model to drive greater customer proximity, a relentless focus on commercial excellence, the most impactful pipeline in BD history and record levels for operational efficiency, quality and reliability." Tom Polen

Industry Context

The company is undergoing a significant strategic transformation to become a focused, pure-play MedTech leader, aligning with broader industry trends towards specialization and high-growth segments. Its innovation pipeline targets attractive markets such as Biologic Drug Delivery, Advanced Patient Monitoring, Urinary Incontinence, and Advanced Tissue Regeneration, indicating a focus on high-value medical solutions. The leveraging of AI, robotics, and new material science in its innovation strategy reflects the increasing technological integration across the healthcare industry. With over 90% of its total revenue from consumables, the company maintains a stable and recurring revenue base. Its performance and executive compensation are benchmarked against a peer group of leading healthcare equipment and supplies companies, including Abbott Laboratories, Medtronic plc, and Thermo Fisher Scientific Inc., demonstrating its position within the competitive MedTech landscape. Engagement with industry associations like AdvaMed further highlights its active role in shaping the medical technology sector.

Comparison to Industry Standards

• Achieved the most prolific period of organic growth in its 128-year history over the past five years, indicating strong performance relative to its historical trends and potentially outperforming some industry peers.
• Became a leader among its peer group in gross and operating margin expansion, driven by its BD Excellence operating system, suggesting superior operational efficiency compared to competitors like Abbott Laboratories, Medtronic plc, and Thermo Fisher Scientific Inc.
• Maintained its position as a member of the S&P 500 Dividend Aristocrats Index with its 54th consecutive year of dividend increases, demonstrating exceptional consistency and reliability in shareholder returns compared to global benchmarks.
• Achieved the lowest CapEx-to-revenue ratio in over a decade, indicating efficient capital deployment and strong asset utilization relative to its past performance and potentially industry averages.
• Executive compensation is benchmarked against a peer group including Abbott Laboratories, Agilent Technologies, Inc., Baxter International Inc., Boston Scientific Corporation, Danaher Corporation, GE Healthcare Technologies, Inc., Medtronic plc, Stryker Corporation, Thermo Fisher Scientific Inc., and Zimmer Biomet Holdings, Inc., aiming for competitive pay within the 50th and 75th percentile of this group.
• Relative Total Shareholder Return (TSR) is used as a modifier for Performance Unit payouts, comparing BD's stock performance against the S&P 500 Healthcare Equipment & Supplies Index, ensuring alignment with industry-specific shareholder value creation.

Management Changes

Corporate Governance

Legal Proceedings

• Fiscal year 2025 financial adjustments included charges related to product liability and certain other legal matters.
• A charge was accrued for an estimated liability related to an SEC investigation concerning reporting issues involving BD Alaris infusion pumps prior to 2021.
• Accruals were recognized relating to the Italian government medical device pay back legislation.

Related Party Transactions

• BD anticipated making an investment of $2 million over a five-year period in TEAMFund, LP II, a for-profit limited partnership established by Timothy Ring, a director, and his wife, Kathryn Gleason. This investment, representing approximately a 1.3% limited partnership interest, was approved by the Governance Committee due to its potential to provide insight into emerging technologies and align with BD's health equity initiatives. Mr. Ring and Ms. Gleason do not benefit financially from the Partnership.

Stakeholder Impact

• **Shareholders**: Expected to benefit from value unlocked by the Waters RMT transaction, including share repurchases and debt reduction. Strong financial performance (record revenue, adjusted EPS) and consistent dividend increases (54th consecutive year) enhance shareholder returns. Enhanced corporate governance practices and the proposed equity plan amendment aim to align management and director interests with shareholders.
• **Employees**: Benefit from a competitive compensation program, including equity awards, and a focus on a 'Healthy Workforce and Communities' through initiatives like professional development, talent mobility, career growth opportunities, and Associate Resource Groups (ARGs). The pay equity assessment reinforces fair compensation practices.
• **Customers**: Expected to receive an 'exceptional customer experience' through world-class commercial capabilities, breakthrough innovations (e.g., BD Incada, BD Pyxis Pro), and a commitment to 'exceptional quality, reliable supply.'
• **Creditors**: Will benefit from the company's commitment to debt repayment using proceeds from the Waters RMT transaction and continued progress towards a ~2.5x net leverage target, indicating improved financial stability.
• **Communities/Society**: Positively impacted by the 'Together We Advance' Corporate Sustainability strategy, which includes 2030+ goals for environmental stewardship, innovation and product impact, responsible supply chain, healthy workforce and communities, and transparency. This aligns with health equity initiatives and UN Sustainable Development Goals (SDGs).

Next Steps

• Complete the value-creating combination of Biosciences and Diagnostic Solutions with Waters Corporation.
• Allocate at least half of the expected $4 billion cash proceeds from the Waters RMT for share repurchases, with the balance for debt repayment.
• Continue progress towards achieving a ~2.5x net leverage target.
• Launch the new 'Excellence Unleashed' growth strategy across three strategic priorities: Compete, Innovate, and Deliver.
• Meaningfully increase the value and pace of the innovation pipeline through innovation excellence and investment.
• Hold the 2026 Annual Meeting of Shareholders on January 27, 2026, to vote on director elections, auditor ratification, executive compensation, and an equity plan amendment.
• Register the additional shares under the Securities Act of 1933 as soon as practicable following the 2026 Annual Meeting, if the equity plan amendment is approved.
• Conduct the next consultant-facilitated board self-evaluation in 2027.
• Anticipate the closing of the investment in TEAMFund, LP II in fiscal year 2026.

Key Dates

Recommendation

The filing presents a compelling investment case, highlighting a successful strategic transformation into a focused MedTech leader. Record fiscal year 2025 revenues and adjusted diluted EPS demonstrate strong operational and financial performance. The planned Reverse Morris Trust transaction with Waters Corp. is a significant value-unlocking event, providing substantial cash proceeds earmarked for shareholder returns via share repurchases and debt reduction. The new 'Excellence Unleashed' strategy, coupled with a robust innovation pipeline leveraging advanced technologies like AI and robotics, positions the company for sustained future growth in attractive markets. The company's consistent dividend increases (54 consecutive years) and strong corporate governance further enhance its appeal. While minor operational adjustments due to tariffs and a shareholder proposal issue are noted, the overall strategic direction, financial health, and commitment to shareholder value creation are exceptionally positive, warranting a 'strong buy' recommendation.

Keywords

Medical Technology, MedTech, SEC Filing, Proxy Statement, Corporate Governance, Financial Performance, Shareholder Meeting, Executive Compensation, Equity Plan, Dividends, Share Repurchase, Portfolio Optimization, Innovation, AI, Robotics, Supply Chain, Sustainability, Risk Management, BD2025, Excellence Unleashed, Waters Corporation, Reverse Morris Trust